IMV Inc. (IMV) Reports Q1 Loss of $0.10

IMV Inc. (NASDAQ: IMV) reported Q1 EPS of ($0.10), versus ($0.14) reported last year. Revenue for the quarter came in at $69 thousand, versus $51 thousand reported last year.

“We remain focused on our commitment to provide effective and well-tolerated immunotherapies for patients with difficult-to-treat cancers. Clinical programs with our lead immunotherapy are progressing as expected, and we are pleased that maveropepimut-S will soon be evaluated in subjects with HR+/HER2- breast cancer, another unmet medical need,” announced Fred Ors, Chief Executive Officer at IMV. “We are reaching another milestone as our second immunotherapy, DPX-SurMAGE, is entering into a clinical trial in patients with bladder cancer later this year with the support of a C$1.8M grant. Also, we will now benefit from the expertise of two new board members who are recognized strategic thought leaders in immuno-oncology.”

For earnings history and earnings-related data on IMV Inc. (IMV) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Movano (MOVE) Misses Q2 EPS by 195c